File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma

TitleNon-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma
Authors
KeywordsMultiple myeloma
Myeloablative agents
Transplantation
Issue Date2004
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2004, v. 10 n. 2, p. 77-83 How to Cite?
AbstractObjective. To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. Design. Retrospective study. Setting. Bone marrow transplantation unit at a university hospital, Hong Kong. Patients. Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002. Intervention. Fludarabine (90 mg/m 2) and total body irradiation (300 cGy) were given as conditioning regimens, followed by non-myeloablative allogeneic stem cell transplantation. Main outcome measures. Engraftment, regimen-related toxicity, treatment-related mortality (in the first 100 days), incidence of graft-versus-host disease, chimerism, disease response, and survival rate. Results. All 10 patients had active disease before transplantation. The donors were eight human leukocyte antigen-matched siblings, a mismatched sibling, and a matched daughter. Satisfactory engraftment before day 21 was achieved without early treatment-related mortality. Five patients developed full donor chimerism by day 28 and three other patients had 100% donor chimerism by day 100. Acute graft-versus-host disease developed in six patients (five with grade III and one with grade IV disease), and chronic graft-versus-host disease developed in eight patients (four with extensive disease). Complete remission and partial response were achieved in three and four patients, respectively. Three patients did not respond to treatment, and one case of relapse was observed. Only one patient, who had shown a partial response, received donor lymphocyte infusion; seven patients received thalidomide for graft-versus-host disease with or without graft-versus-myeloma effect. All patients were alive after a median follow-up of 1 year. Conclusion. Non-myeloablative allogeneic stem cell transplantation for multiple myeloma is effective, has low toxicity, and results in low treatment-related mortality. Studies of more cases with longer follow-up durations are required.
Persistent Identifierhttp://hdl.handle.net/10722/45150
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279
References

 

DC FieldValueLanguage
dc.contributor.authorMa, SYen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2007-10-30T06:18:25Z-
dc.date.available2007-10-30T06:18:25Z-
dc.date.issued2004en_HK
dc.identifier.citationHong Kong Medical Journal, 2004, v. 10 n. 2, p. 77-83en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45150-
dc.description.abstractObjective. To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. Design. Retrospective study. Setting. Bone marrow transplantation unit at a university hospital, Hong Kong. Patients. Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002. Intervention. Fludarabine (90 mg/m 2) and total body irradiation (300 cGy) were given as conditioning regimens, followed by non-myeloablative allogeneic stem cell transplantation. Main outcome measures. Engraftment, regimen-related toxicity, treatment-related mortality (in the first 100 days), incidence of graft-versus-host disease, chimerism, disease response, and survival rate. Results. All 10 patients had active disease before transplantation. The donors were eight human leukocyte antigen-matched siblings, a mismatched sibling, and a matched daughter. Satisfactory engraftment before day 21 was achieved without early treatment-related mortality. Five patients developed full donor chimerism by day 28 and three other patients had 100% donor chimerism by day 100. Acute graft-versus-host disease developed in six patients (five with grade III and one with grade IV disease), and chronic graft-versus-host disease developed in eight patients (four with extensive disease). Complete remission and partial response were achieved in three and four patients, respectively. Three patients did not respond to treatment, and one case of relapse was observed. Only one patient, who had shown a partial response, received donor lymphocyte infusion; seven patients received thalidomide for graft-versus-host disease with or without graft-versus-myeloma effect. All patients were alive after a median follow-up of 1 year. Conclusion. Non-myeloablative allogeneic stem cell transplantation for multiple myeloma is effective, has low toxicity, and results in low treatment-related mortality. Studies of more cases with longer follow-up durations are required.en_HK
dc.format.extent429960 bytes-
dc.format.extent2379037 bytes-
dc.format.extent2789 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectMultiple myelomaen_HK
dc.subjectMyeloablative agentsen_HK
dc.subjectTransplantationen_HK
dc.subject.meshHematopoietic Stem Cell Transplantation - adverse effects - methodsen_HK
dc.subject.meshMultiple Myeloma - diagnosis - mortality - therapyen_HK
dc.subject.meshTransplantation Conditioningen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshTransplantation, Homologousen_HK
dc.titleNon-myeloablative allogeneic peripheral stem cell transplantation for multiple myelomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=10&issue=2&spage=77&epage=83&date=2004&atitle=Non-myeloablative+allogeneic+peripheral+stem+cell+transplantation+for+multiple+myelomaen_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid15075426en_HK
dc.identifier.scopuseid_2-s2.0-1842713262en_HK
dc.identifier.hkuros87682-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1842713262&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue2en_HK
dc.identifier.spage77en_HK
dc.identifier.epage83en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridMa, SY=7403725725en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats